Another important feature of hyaluronic acid is its binding capacity to CD144 and CD168 (also known as receptor for hyaluronan-mediated motility, RHAMM) receptors, making it suitable to target cells that overexpress these receptors as cancer cells (squamous cell carcinoma, ovarian, colon, stomach, glioma, and many types of leukemia, lymphoma, and multiple myeloma) [33, 37–39]. This evidence concerns the gene HMMR and lymphoma.